Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 [Yahoo! Finance]
Cognition Therapeutics, Inc. (CGTX)
Company Research
Source: Yahoo! Finance
clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study ( NCT05225415 ) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the AD/PD™ 2026 Alzheimer's & Parkinson's Diseases Conference. The conference is being conducted March 17-21, 2026 in Copenhagen, Denmark. The analysis focuses on Zervimesine's treatment effects on the behavioral and psychiatric symptoms most commonly associated with DLB. “In the Phase 2 ‘SHIMMER' study, we saw a treatment effect across neuropsychiatric, cognitive, motor, and global function domains with zervimesine treatment compared to placebo,” explained Anthony Caggiano, MD, PhD , Cognition's CMO. “This effect was particularly robust against DLB's behavioral and psychiatric symptoms, which have been identified as important to patients and care partners. We're presenting a breakdown of zervimesine's effect relative to placebo on the components of the neuropsychiatr
Show less
Read more
Impact Snapshot
Event Time:
CGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGTX alerts
High impacting Cognition Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CGTX
News
- Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial ResultsGlobeNewswire
- Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026GlobeNewswire
- Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis [Yahoo! Finance]Yahoo! Finance
- Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) PsychosisGlobeNewswire
CGTX
Earnings
- 5/7/25 - Miss
CGTX
Sec Filings
- 3/2/26 - Form 8-K
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- CGTX's page on the SEC website